← All stocks

NovoCure Ltd

NVCR Net selling
CIK 0001645113 #2023 in the set updated 18 Sep 2026
Bought (120 mo)
$2.96M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$575.03M
$528.41K on a plan · $347.55M straight out of an exercise
Sold at will
$226.95M
467 of 884 sales
Net
−$572.07M
−$223.99M against sales at will

By person

33 insiders · 969 transactions
17.3×

Frank Leonard holds 17.3 times base salary in stock. $9.89M of shares against $570.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Frank Leonard last reported holding, valued at $17.93, the price Ordinary Shares was last bought or sold at on the open market here, on 4 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Danziger Asaf
Director
$509.54K (3)
$201.82M (101) scheduled
−$201.31M
604,831
$10.85M
−48.8%
DOYLE WILLIAM F
Executive Chairman
$73.23M (51)
−$73.23M
1,320,075
$23.67M
−94.1%
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
$64.69M (183) scheduled
−$64.69M
530,347
$9.51M
+27.2%
Ambrogi Michael J.
Chief Operating Officer
$44.13M (73) scheduled
−$44.13M
441,734
$7.92M
−26.1%
Longsworth Todd Christopher
General Counsel
$31.10M (57) scheduled
−$31.10M
130,176
$2.33M
+86.7%
Shah Pritesh
Chief Growth Officer
$357.05K (1)
$26.50M (77)
−$26.14M
202,397
$3.63M
+113.1%
Kirson Eilon D.
Chief Science Officer
$24.29M (19) scheduled
−$24.29M
152,408
$2.73M
−14.4%
LEUNG GABRIEL
Director
$24.16M (52) scheduled
−$24.16M
101,109
$1.81M
Pomona Capital VII, L.P. entity
10% owner
$18.61M (4)
−$18.61M
2,741,925
$49.17M
−28.1%
Palti Yoram
Chief Technology Officer
$15.75M (73)
−$15.75M
1,041,054
$18.67M
−42.8%
Leonard Frank X
Chief Executive Officer
$13.29M (64)
−$13.29M
551,470
$9.89M
+232.8%
VERNON W ANTHONY
Director
$9.19M (4)
−$9.19M
209,267
$3.75M
−16.0%
PHILLIPS CHARLES G III
Director
$9.02M (11) scheduled
−$9.02M
3,359
$60.24K
Benaim Ely
Chief Medical Officer
$5.72M (26) scheduled
−$5.72M
64,947
$1.16M
+45.7%
Weinberg Uri
Chf Medical and Innovation Ofr
$5.60M (16) scheduled
−$5.60M
303,496
$5.44M
+428.8%
Cordova Ashley
Former Chief Executive Officer
$996.86K (1)
$5.45M (26) scheduled
−$4.45M
458,463
$8.22M
+754.1%
Perlhagen Gert L.
Director
$866.25K (1)
+$866.25K
6,125,000
$109.84M
Paravasthu Mukund
Chief Operating Officer
$810.07K (12)
−$810.07K
72,832
$1.31M
+1,888%
Burke William Patrick
Chief Human Resources Officer
$651.32K (10)
−$651.32K
66,447
$1.19M
+153.5%
HILLEMAN JERYL L
Director
$508.02K (4)
−$508.02K
25,471
$456.78K
Brackmann Christoph
Chief Financial Officer
$231.80K (3)
$85.31K (1)
+$146.49K
182,842
$3.28M
+176.3%
Scannell Timothy J
Director
$86.77K (3)
−$86.77K
25,898
$464.44K
+34,431%
Puri Michal Nath
Chief Human Resources Officer
$74.89K (5)
−$74.89K
203,227
$3.64M
+20,322,600%
Hung David
Director
$63.72K (2)
−$63.72K
32,075
$575.22K
Ocean Allyson J
Director
$63.71K (2)
−$63.71K
22,934
$411.29K
Stafford Kristin
Director
$63.70K (2)
−$63.70K
22,934
$411.29K
Leupin Nicolas
Former Chief Medical Officer
$48.54K (4)
−$48.54K
102,979
$1.85M
Madden Martin J.
Director
$22.38K (2)
−$22.38K
31,086
$557.48K
+7,337%
Wyss Hansjoerg
10% owner
9,780,397
$175.40M
−9.3%
Ben Arye Barak
General Counsel
243,752
$4.37M
+1,337%
Giladi Moshe
Chief Science Officer
69,771
$1.25M
+274.2%
Burkoth William T.
Director
6,145
$110.20K
Melnyk Peter M.
Chief Commercial Officer
2,403
$43.09K

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Insider
Date
Role
Action
Shares
Price
Amount
Leonard Frank X
2 Jun 2025
EVP, Pres., Novocure Oncology
Sold on a plan
1,879
$19.01
$35.72K
Leonard Frank X
2 Jun 2025
EVP, Pres., Novocure Oncology
Sold on a plan
6,600
$17.99
$118.73K
Leonard Frank X
2 Jun 2025
EVP, Pres., Novocure Oncology
Sold on a plan
21,717
$17.22
$373.96K
Showing 250 of 969 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 687
Amendments (4/A) skipped 11
Filings about a different issuer 0
Unreadable filings 0
Joint filings 4
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 414
Sales at will 467
Transactions with no price 2
Shares from compensation/vesting 43,129,995
Sales filed before the plan box existed 394
History held since 6 Dec 2016